Internet Drug
Pharmaceutical News & Information; Updated Daily Since 1998

Drug Coupons Database
Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here

Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- Drug Wonks
- World Of DTC
ΏYour Link Here?
Let's Trade

Pharmaceutical News Harvest (TM)
Please note: In observance of the Presidents Day holiday,
this site will next be updated the evening of 2/15/16

2/12 Fast Takes
Xarelto Lawsuits Now Exceed 3,000 in Number
Legal Bay Press Release
Incyte Falls on Jakafi Solid-Tumor Setback
The Street
Study: The Risk Of Developing Dementia Is Declining
The Way Drugs Are Prescribed Is Changing [Infographic]
Sanofi tried and failed with Afrezza. Why does MannKind still think it can win?
Fierce Pharma
FDA designated a record number of orphan drugs last year

2/12 Laugh All You Want - Pain Pills Make It Hard Move Your Bowels
- Opioid constipation is serious medical condition
No joke: Opioid constipation drugs are serious business …  40 to 90 percent of opioid users as some point experience OIC … a lot of people who suffer from that increasingly common -- and often painful -- issue likely weren't chuckling … 59 million prescriptions for opioids were written 2012… [CNBC]

Glaxo's "Ah Ha" Moment Regarding Break Up, Pricing Policies
Glaxo U.S. Pharma Head Says 'Unfettered Pricing' Days Are Gone … willing to consider a breakup, although that may not happen for a year or two …  three divisions: pharmaceuticals, vaccines and consumer, which sells household products like Theraflu … [Bloomberg]

Teva Takes a Shellacking As Copaxone Sales Disappoint,
Delay Allergan Generics Deal Seen

Teva Shares Plunge as Sales of Copaxone Disappoint … Copaxone fell short of expectations and the Israeli company signaled a delay in completing the acquisition of Allergan Plc's generics unit … [Bloomberg]

Wall Street Hates Mylan's Mega Meda Deal
- Shares implode 15% as analysts imply 92% premium is too much to bear
Mylan Slumps on $7.2 Billion `Wealth Destroying' Meda Deal … the price paid versus other potential alternatives makes little sense … We simply do not understand some of the choices made over the last 18 months, and despite some strategic rationale with this recent Meda proposal, it would appear that  …[ Bloomberg]
Mylan shareholders recoil after $7.2B deal for Meda … Investors are saying they don't want $7 billion taken out of (Mylan's) coffers …  investors may also be worried because 70% of cross-border acquisitions don't succeed …[USA Today]

The Other Drug Shkreli Price Gouged But Nobody Complained
-  Compounding pharmacy to make cheaper alternative to Retrophin's Thiola (Tiopronin)
- Generic drugs with no competition is recipe for price gouging
This company has a solution to drug price gouging -- and a new target … drug also a rare disease and is owned by a company that hiked its price substantially -- by 2000% in 2014 -- without any real justification …  cystinuria is a chronic condition that requires a starting dose of about eight pills a day, at Retrophin's price it typically costs more than $87,000 a year … [Yahoo Finance]

Pharma Industry Wants To Punish  On India For Protectionism,  Flouting Patents
- Urges Obama to keep India on official bad guy list
Keep India on list of bad patent players, pharma urges Obama administration … imposes high tariffs and taxes on medicines, discriminates against foreign drug makers through price controls, and creates a "burdensome environment" for clinical research … concern about protecting its domestic pharmaceutical industry … [Pharmalot]

Fast Takes
Making the Case for the Value of Co-pay Cards
Myelofibrosis: CTI-Baxalta Drug Withdrawn, Removing Potential Incyte Rival
Investor's Business Daily
Cancer Took Google Exec's Wife. Now He's CEO Of One Of The Most Audacious Cancer Startups In Years
AstraZeneca Targets Africa Sales Boost
Mylan Makes $7.2 Billion Deal for Meda
Humana May Withdraw From Obamacare Exchanges
New Pharmacies And PBM Growth Boost CVS Health Profits

Express Claims Biosim Remicade Will Save USA $250 Billion
- Panel votes 23:1 to approve; FDA nod forgone conclusion
A new drug that could save the US billions of dollars just got one step closer to approval … price cut won't be as low as it is with most generics. It doesn't take as much time, energy, and money to make a generic medicine. Eich said that to develop a biosimilar, it usually takes about eight years and costs about $250 million …[Business Insider]
Editor's Note: I would not expect huge discounts or seismic market share shifts overnight for biosim drugs.  It's like cars in a sense; A new baseline Chevy  Camaro goes for $25.7 K.  Ford's not going to sell you a comparable Mustang for $12K.  Ford charges $24.2 K .  If the Fords steal lots of share, Chevy can offer a rebate (sound familiar?) to come closer to the price of the competition.  The unknown quantity is what exactly the indications and warnings are for the knockoff, how huge the rebates the PBM's can extract and who is willing to sacrifice margins to maintain share.  I'm glad I'm not a pharma actuary.

2/11 Gilead Cocky Regarding Merck Hep C Pill Prospects
- Merck's Zepatier poses a new challenge to Gilead's best-selling drug, but maybe it's not as threatening as some think.
Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck … we've got a pan-genotypic hep C drug potentially coming on the market ….  testing that needs to be done [before prescribing Zepatier] ahead of time to see if there's some polymorphisms, because Zepatier didn't work very well within patients that had those polymorphisms … insurers and payers are taking a more measured approach in approaching the Merck drug …[Motley Fool]
Editor's Note: This battle will be won or lost at the PBM level.  Gilead dodged a bullett when Viekira Pak developed safety issues requiring an updated warning in its label.  However, PBM's can easily step edit Gilead's clinically superior product.  They might say the Gilead pill may only be used if the patient fails the genotype blood test and you need to fax in a copy of the results before you get the approval.  That tactic shoots Gilead's cockiness in the ass.  These days price trumps compliance and efficacy. 

Pharmalot: Shkreli Is Cut From The Same Cloth As The Other Drug Execs
- Shkreli's arrogance, willingness to make huge jump rather than increments  makes him a standout
Pharma industry has more in common with Martin Shkreli than it likes to admit … Of about 3,000 brand-name medicines, prices more than doubled for 60 products, and at least quadrupled for 20 of those, since December 2014 … Shkreli may be a convenient whipping boy, but the controversy over high prices began simmering long before he targeted pharmaceuticals as a pot of gold …[Pharmalot]

Yet Another India Drug Factory Warning
- Maker of bulk ingredients for major industry players
FDA warns another Indian drug maker for a laundry list of problems … customers are Merck, Pfizer, and AstraZeneca … email excerpts and noting how employees admitted to lying … routinely retested samples without justification, and manipulated testing parameters to obtain passing results …[Pharmalot]

Novo CEO: In His Own Words
[AUDIO] Novo Nordisk CEO: Very Fierce Competition In The Sector … espite fierce competition in the pharmaceutical industry, Novo Nordisk's CEO Lars Rebien Soerensen says that the company's forward guidance remains strong …[Bloomberg]
Editor's Note: 6 minute audio; interesting.

Obama Goes After The Drug Companies
- Seeks to negotiate prices of certain drugs
Obama Targets Drug Costs in Health Section of Final Budget … authority to negotiate prices for biologic drugs and other expensive medicine … Drugmakers would be also required to increase the rebate they give to Medicare patients  … require drugmakers to disclose information on their costs …[Bloomberg]

Six Years Of College For This?
- Pharmacists are the new drug enforcement personnel like it or not
Opioid crisis puts pharmacists on the front line, pressed to serve as drug cops … pharmacists are increasingly, and controversially, called upon to play drug cop -- to turn away abusers, to reject phony prescriptions, and to protect their inventory of pills from criminals …[STAT]

2/10 Panel Likes Biosimilar for Remicade
FDA Panel Backs Lower-Cost Version of J&J's Top-Selling Drug .... The non-binding recommendation could clear the way for the cheaper medication from Celltrion, which would only be the second in a new class of quasi-generic biotech drugs to reach the U.S. market .... ABC News

2/10 Medicare Wants to Revamp How Medical Benefit Drugs Are Reimbursed
Medicare Weighing Changes to Doctor Drug Payments .... The memo tells Medicare contractors who process payments to set up a system allowing the government to vary by geographic location how much it reimburses doctors for the drugs they administer. The government could then set up a pilot program to test how limiting reimbursement in Medicare Part B affects doctors' choice of drugs .... Bloomberg

2/10 For Sanofi, Diabetes Drug Sales Off, But Praluent, Aubagio Climb
Sanofi Says 2016 Profit Won't Grow as Bestseller Lantus Fades .... [CEO] Brandicourt is betting that new therapies such as Praluent, a powerful cholesterol treatment that first went on sale in July, the Toujeo insulin and Aubagio for multiple sclerosis, will help make up for the Lantus revenue shortfall. .... Bloomberg

2/10 Why Is US Life Expectancy Shorter than Other Countries? Guns, Drugs, and Crashes
Preventable injury deaths shorten U.S. life expectancy .... Underlying the life expectancy differences was a rate of 865 deaths per 100,000 men in the U.S. in 2012, compared to 772 per 100,000 men in other countries that year. A similar difference was seen among women, with a rate of 625 deaths per 100,000 in the U.S. compared to 494 deaths per 100,000 in other countries .... Reuters

2/10 How Movantik Ended Up in a Super Bowel Ad
OICisDifferent: The Drug Behind The Super Bowl 50 Constipation Ad .... Movantik's effectiveness on constipation was only 5% to 15% greater than placebo in its clinical registration trials. But their patient population was highly opioid-tolerant, averaging 140 mg/day morphine equivalents. So, it's pretty impressive that Movantik had that degree of efficacy. .... Forbes/David Kroll

2/10 New PWC Report: New Focus on Data Integrity in Quality Evaluations
Major shift ahead in how FDA regulates drug quality .... Parts of the pharmaceutical industry continue to struggle with drug quality. A major shift in the way the FDA oversees drug quality could pose new challenges for companies with inadequate control over their manufacturing facilities and supply chains .... pwc

2/10 Here is a Recommended Trends Piece for Marketers
New consumer concerns harder for health brands to swallow .... When prescribed a drug, roughly one out of every two patients asks the physician questions about it, nearly a third ask their pharmacist, and only 8% go to the drug website .... MM&M
See also: Same report data; but with zippy infographic

2/10 Another Delay for Eteplirsen Decision
FDA delays decision on Sarepta's experimental Duchenne treatment .... The Food and Drug Administration has extended by three months the date by which it will issue its ruling on Sarepta's new drug application for its drug, called eteplirsen. The agency is now scheduled to make a decision by May 26. .... Boston Globe

2/10 In Oregon, Providing Hep C Drugs to All the Prisoners Who Need It, Would Cost 4X the State's Whole Prison Health Care Budget
Are States Obligated to Provide Expensive Hepatitis C Drugs? .... Federal court cases have established a lower standard for prison health care. Prisons must provide health care to inmates, but can deliver it as they see fit, as long as they don't demonstrate "a deliberate indifference to serious medical need." .... Stateline

2/10 Internet Drug News Fast Takes:
Veterans' hospital performance similar to other U.S. hospitals
CVS Health's Drug Sales Are Booming
NICE u-turn backs use of Amgen's Repatha
Pharma Times
Astellas Pharma names new president of Americas Operations
American Pharmacy News
CBT May Work As Well As Meds in Major Depressive Disorder
Health Day News
Doctors Should Screen Teens for Major Depression, U.S. Task Force Says
Health Day News

Pfizer Names Executives To Lead Proposed Allergan Merger
Pfizer Press Release
Talk of generic TNF inhibitors hurts JNJ share price
GSK's slow-off-the-blocks breathing med Anoro (umeclidinium and vilanterol) gets a leg up from Incruse sidekick
Fierce Pharma Marketing
The Top 15 Pharmacies of 2015 Ranked by Revenues
Drug Channels

Day In The Life Of A Medical Device Rep
- Cafι Pharma original content
What It's Like To Work In Device Sales … not uncommon for the surgeon to look at me and ask, "what should I do now" … I can have four surgeries in four different hospitals. Those can be long and stressful days … Some companies have reps assist in surgeries for two years before they work in the field completely by themselves …[Cafι Pharma]

:::::::::::::::::::::::::::: Just For Laughs; Satire:::::::::::::::::::::::::::::::
NicoDerm Introduces New Nicotine Eye Patch … delivering a steady flow of therapeutic nicotine directly into the bloodstream through the optic nerve … We recommend, however, that users don't put on more than one at a time … [The Onion]
Editor's Note: Click HERE for more funny, satirical  pharmaceutical news and information.

The Risk Of The Backfiring Celebrity Drug Advertisement
Celebrity drug ads: Opportunity or PR disaster? … If they say something dumb on social media or act inelegantly while out in public, they'll get called out for it in a way that most of the rest of us wouldn't. Don't buy it? Ask Subway how it feels about binding its brand to Jared Fogle nowadays … [MMM]

Poop & Toenails: Twitterverse Had Fun Pharma's Superbowl Ads
Valeant, AstraZeneca played the Super Bowl ad game, but did they win? … All three ads tanked in USA Today's annual viewer poll and came in at the very bottom of the list of its 63 consumer-ranked ads: AZ's OIC was No. 60, Xifaxan was No. 62 and Jublia came in dead last at No. 63 …[Fierce Pharma Marketing]
Related: Twitterverse finds unofficial Super Bowl mascot in diarrhea medication commercial … [EW]
Related: Poop had its very own Super Bowl 50 moment … opioid-induced constipation. The clip -- from AstraZeneca and Daiichi Sankyo -- fittingly stars a man in desperate longing for a satisfying bowel movement …[Mashable]

Drugmakers See Linked In As Appropriate Platform For Social Media Marketing
- Lack of ability to post troll comments seen as safety net
'Safe' social network LinkedIn emerges as popular marketing tool for pharma … we've seen a huge growth in having these companies consider LinkedIn as a channel … nMail, in which sponsored messages are sent directly to targeted LinkedIn members inboxes, tends to be "safe" for pharma because email bypasses any open comment possibilities …[Beth Snyder Bulik, Fierce Pharma Marketing]

Novartis Offers Guarantee On Entresto (sacubitril/valsartan)
If Patients Go To Hosp W/ CHF, PBM's Get Rebates
Novartis sets heart-drug price with two insurers based on health outcome … payments will be based on a reduction in the proportion of customers who are admitted to hospital for heart failure … value-based agreement with Novartis that is based on the drug replicating results that it achieved during clinical trials …[Reuters]
Related: Cigna Implements Value-Based Contract with Novartis for Heart Drug Entresto … [Cigna Press Release]

Senator Highlites Conflict Of Interest On Pain Drug Approval Expert Panel
Senator scrutinizes pharma links on government pain panel …  a third of panelists at a December meeting of the Interagency Pain Research Coordinating Committee had apparent financial ties to painkiller manufacturers, including the maker of OxyContin … One panelist holds a chair at the center created by a $1.5-million donation from Purdue …[AP]

Fast Takes
Newest Drug Shortage: Sodium Bicarbonate Injection, USP
Doc Gets 30 Years For Running Pill Mill Linked To 12 Deaths
A bankrupt KaloBios may still buy Chagas drug that Shkreli wanted to acquire-and-hike prices anyway
Biopharma Dive
FDA Rejects Expanded Use of Vertex Cystic Fibrosis Drug
India's Pharmaceutical Market to Skyrocket from $20B to $55B by 2020
Sun Pharma rolls out first U.S. copycat to $4.5B cancer drug copycat Gleevec (imatinib)
Tracy Stanton, Fierce Pharma

Shire Takes 2nd Bite At Dry Eye Apple
Resubmits lifitegrast application to FDA
Shire's self-described blockbuster eye drug lines up for FDA do-over … FDA rejected Shire's first application in October, unmoved by a Phase III trial in which the treatment succeeded on only one of its two primary endpoints …[Fierce Pharma]

Real Shkreli Back Story: Rube Goldberg Drug Pricing System Is Broken
- Lack of transparency at every level makes for Gordian Knot; too easy to game the system
The Real Lesson of the Shkreli Circus … beyond the theatrics, the hearing highlighted what an opaque and broken mess drug pricing is in the United States … targeted old drugs with small patient populations in the hope payers, physicians, and patient groups wouldn't notice…[Bloomberg Gadfly]

Patient In Suspended Muscular Dystrophy Trial Dies
A patient in Akashi's suspended Duchenne MD trial dies … ittle more than a week after Cambridge, MA-based Akashi Therapeutics suspended its study of a new drug for Duchenne muscular dystrophy (DMD) after a patient was sent to the hospital, the biotech reports that the trial subject has died …[Fierce Biotech]

:::::::: Worth A Click:::::::::::::::::
Pharma Blogger Pioneer Launches Curated Online Newspaper
Pharma Marketing Pundit, Publisher & Chief Pharmaguy at
launches new online 'zine.  We think it's a winner.  See for yourself!

FDA Approval Of Pfizer, Celltrion Remicade (infliximab) Knockoff Looks Likely
FDA Staff Supports Remicade Biosimilar…  analyst said the broad interpretation of Remsima's potential effectiveness might signal its approval for treating all diseases in which Remicade can be marketed.… Pfizer and Celltrion want to market Remsima in the U.S. as a cut rate copy of infliximab or Remicade … Some medical analysts expect the drug to sell for at least 25% less …

Biosims: Interchangeability On The Table, Bureaucratic Overload Predicted
Woodcock expects surge of biosimilar applications … plans to release long-awaited guidance on interchangeability and labeling of biosimilars this year.  … "What I'm concerned about is that this program is going to explode," said Woodcock. "I'm concerned that we will not have the staff because we're always waiting to catch up … [BioCentury]
Related: Liability: The big biosim legal scuffle the industry should be anticipating … Are biosimilars going to be exposed to a higher degree of risk of product liability lawsuits than generic drugs? And how does that weigh into the overall economics of biosimilars? …[Biopharma Dive]

Remember Pain Creams? FBI Investigates Poss $500 Million Web Of Fraud
-Tricare paid $1.75 Billion for pain creams in 2015 alone
U.S. Probes Possible Fraud Linked to Compounding Creams … more than $10,000 for a single tube … allegations that some of the products provide little to no medicinal value … pitched on the Internet or by telemarketers as a safe way to help athletes heal quickly or alleviate types of pain or cramping,…[WSJ]
Related: Pharmacies push pricier drugs to Tricare users … compound pharmacy marketers have been cold-calling military families and retirees to persuade them to apply for specialty prescriptions like pain creams, wound ointments and erectile dysfunction medications …[Military Times]
See Also: Cafι Pharma threads regarding pain creams and selling of pain creams (sales compensation, etc),

Japan: Radical Changes Coming To Planet's #2 Pharmaceutical Market
Japan Takes Aim at Ballooning Drug Prices as Costs Strain Budget … For years, price was not a big factor in the Japanese pharma market as the national health-care system absorbed costs, one reason why the penetration of generics was much lower than other economies … [Japanese government] would like to see generics make up about 80 percent of prescriptions in Japan from about 50 percent now … Bloomberg]

PhRMA Launches Ad Blitz Aimed At Lawmakers
- Using Facebook to pinpoint target people who make the decisions
Drug Industry Launches Ad Campaign Aimed at Lawmakezrs …  Websites like Facebook promise to deliver ads to specific audiences based on characteristics including their location, occupation and keyword search history. … ads are running on social-media sites like Facebook, LinkedIn and Twitter, because PhRMA wants to target federal and state lawmakers, policy analysts and other political "influencers …

2/5 Senators' Holds on Califf Finally Get FDA to Revisit Opioid Policy
FDA Will Act on Pain Pill Abuse After Senate Blocks Nominee .... Opioid addiction has become a major issue in the presidential race, at the White House and in Congress, where Robert Califf, President Barack Obama's nominee to head the FDA, has been held up in the Senate because of concerns about how the epidemic is being handled .... Bloomberg

2/5 Stem Cell Treatment Cures Diabetes in Animals; Now in Human Tests
Johnson & Johnson, ViaCyte testing possible diabetes cure .... The therapy involves inducing embryonic stem cells in a lab dish to turn into insulin-producing cells, then putting them inside a small capsule that is implanted under the skin. The capsule protects the cells from the immune system .... AP

2/5 Cognitive Dysfunction in Major Depressive Disorder is Now a Thing
FDA Advisors Support New Indication for Brintellix .... Panelists who voted to approve the indication said the data presented by drugmaker Takeda from two clinical trials showed a small effect on cognition, but this was at least a step toward mitigating an unmet need in depression .... Medpage Today

2/5 Trulicity Pulling Share from Victoza
Novo Nordisk Quarterly Profit Misses Estimates on Victoza .... Victoza, injected daily to mimic the activity of a hormone called GLP-1 that stimulates insulin production, showed the first signs of suffering from the introduction of a rival product called Trulicity by Eli Lilly that only requires a weekly injection .... Bloomberg

2/5 Updated Adult Immunization Schedule
ACIP Approves 2016 Adult Immunization Schedule .... The major changes to the schedule relate to human papillomavirus (HPV), pneumococcal, and serogroup B meningococcal (MenB) vaccines .... HealthDay News

2/5 More than Lip Service: Drug Companies Making Serious Investment in Adherence
Big Pharma's big push to get patients to take their meds .... GlaxoSmithKline has enrolled 3,000 of its employees, retirees, and their family members in North Carolina in a pilot program to better coordinate their health care. Among other things, it uses sophisticated analytics to determine who's not sticking with their medication .... Stat

2/5 New Valeant CEO Wants to Bring Copay Coupons to Medicare
Valeant chief calls on Medicare to allow controversial copay help from pharma .... Copay coupons for patients in Medicare and other government-funded healthcare programs are currently considered an illegal kickback under federal law, forcing drugmakers to limit their assistance to those with commercial insurance .... Fierce Pharma

2/5 Shkreli/Pharma Congressional Hearing Was Amusing Til You Remember These People are Making Life and Death Decisions
Valeant, Turing Slammed as Shkreli Calls Congress 'Imbeciles' .... The hearing in Washington was heated and at times a puzzling spectacle, with controversial pharma executive Martin Shkreli smirking throughout but refusing to testify after invoking the Fifth Amendment, his lawyer being asked at one point to stay seated, and Shkreli later taking to Twitter to insult lawmakers .... Bloomberg (link includes autoplay video highlights)

2/5 Benzodiazepines Off the Hook
Anxiety Meds Valium, Xanax And Ativan May Not Lead To Dementia .... The highest doses of benzodiazepines--use of the drugs daily for a year--were not linked to any increased risk for dementia. Oddly, low and moderate doses (up to one month, or four months, respectively) were linked to a slightly increased risk .... Forbes/Alice G. Walton

2/5 Pfizer Has Vaccinated About a Third of Those Eligible for Prevnar in US
Prevnar's 2015 sales surged to $6B-plus on new CDC nod in adults .... Though prices in Europe are much lower than they are in the U.S., there's a much larger group of eligible adults to draw from, and Pfizer is working to snag favorable reimbursement recommendations from authorities across the continent .... Fierce Pharma Marketing

2/5 Internet Drug News Fast Takes:
CDC: Women who don't use birth control shouldn't drink
Advisory Board Daily Briefing
Hospitals can be 'urban' and 'rural' at same time: U.S. appeals court
Scientists Use Infrared Light to Measure Blood Glucose
FDA Approves Merck's Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)
Company news release
Depomed Wants to Block FDA Approval of Nucynta Generics
Bloomberg BNA

2/4 Here are 2016's Blockbusters
Seven $1 billion-plus drugs seen reaching market in 2016 .... The two top hits of 2016 are tipped to be Intercept Pharmaceuticals' chronic liver disease drug obeticholic acid, with a consensus sales forecast of $2.6 billion in 2020, and Gilead Sciences' new fixed dose HIV drug emtricitabine plus tenofovir alafenamide, on $2.0 billion .... Reuters

2/4 How Valuable Can This Doc Be for Your Brand? Zephyr Says it Knows
The Startup Tracking 'Valuable' Doctors for Big Pharma .... Gathering various strands of information, Zephyr generates profiles that score each doctor's influence and ability to drive sales on a scale of 1 to 10. The software's slick, mobile-friendly interface lets a drug company search in broad or specialized disciplines (from "oncology" to "non-Hodgkin lymphoma") and ranks each person's influence in the chosen field .... Bloomberg

2/4 The 'Foot in the Door' Gets Harder and Harder
4 industry vets sound off on the state of physician-rep access .... Although access has improved, it has done so at the expense of additional restrictions.... the percentage of physicians requiring appointments or restricting access to certain hours has increased more rapidly and is at a three-year high .... MM&M

2/4 Januvia Off Target; Keytruda and Zetia Save Merck's 4Q
Merck's Top-Selling Diabetes Drugs Miss Sales Estimates .... The diabetes pill Januvia is Merck's top-selling product, and sales of $1.44 billion for that drug and another formulation, Janumet, fell short of estimates for $1.67 billion .... Bloomberg

2/4 Nobody Wants to Hear About Your Disease at a Superbowl Party
NFL games are magnets for drug ads. But the Super Bowl isn't. Here's why .... In the lighthearted atmosphere of the Super Bowl, it's an uphill battle to produce a successful ad about a serious health condition .... Stat

2/4 ACCORD Trial Long-term Follow-up
Neutral Long-Term Effect for Intensive Glycemic Control .... The researchers found that a mean of 3.7 years of intensive glucose lowering had a neutral long-term effect on the primary composite outcome (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular disease), death from any cause, and an expanded composite outcome that included all-cause death .... HealthDay News

2/4 Eliquis Sales Doubled Since Last Year; BMS Wants #1 Position
BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa .... Bristol isn't planning to let up on any of the increased spending that helped Eliquis make big gains last year. The company began its DTC efforts in September of 2013, a year in which Q4 Eliquis revenues tallied just $48 million .... Fierce Pharma Marketing

2/4 Ruckus Over Flooding Living Room Heart Failure Ad
Entresto Maker In Deep Water Over Terrifying TV Advertisement .... The ad depicts a middle-aged man in an easy chair reading the newspaper, oblivious to a rising flood that threatens to drown him, though his dog, climbing onto a couch for safety, expresses considerable anxiety .... Cardiobrief

2/4 TrusTED Wants to Put FDA Approvals Up to a Congressional Vote
Sen. Ted Cruz Wants To Change The Way The FDA Approves Drugs .... The RESULT Act would allow for reciprocal approval of drugs, devices and biologics from foreign sponsors in European countries, as well as from Japan, Canada, Australia and Israel. In addition, the bill would allow Congress to overrule FDA rejections of life-saving drugs with a majority vote via joint resolution .... Forbes/John LaMattina

2/4 Viewability Pow-Wow Feb. 4
Pharma, ad agencies press publishers for higher ad viewability standards .... The Internet Advertising Bureau now recommends that 70% of the ad be visible for one second, while individual brands and agencies are pushing for even more, usually 100%. .... Fierce Pharma Marketing

2/4 Internet Drug News Fast Takes:
18 cities in Pennsylvania reported higher levels of lead exposure than Flint
CVS Pharmacy makes Target debut
Chain Drug Review
Cancer drug testimonials tinged with financial interest
Milwaukee Journal-Sentinel
Smart Band-Aid on the Horizon
NY Times
Old Novartis cancer flagship Gleevec heads to pharmacies as lower-cost generic

2/3 Cleveland Clinic Has a Full-Time Pharmacist Dealing with Drug Shortages
Drug Shortages Forcing Hard Decisions on Rationing Treatments .... Such shortages are the new normal in American medicine. But the rationing that results has been largely hidden from patients and the public .... NY Times

2/3 Drug Price Boosts Most Common at End and Beginning of the Year
Shkreli Was Right: Everyone's Hiking Drug Prices .... A survey of about 3,000 brand-name prescription drugs found that prices more than doubled for 60 and at least quadrupled for 20 since December 2014 .... Bloomberg

2/3 Internal E-mails Show Turing Execs Cackling Over $7.2 Million Purchase Orders for Daraprim
Martin Shkreli All but Gloated Over Huge Drug Price Increases, Memos Show .... Martin Shkreli anticipated huge profits from raising the price of Daraprim, belying any notion that helping patients was foremost in his minds .... NY Times

2/3 Baby Powder Link to Cancer?
J&J's Talcum Powder Goes on Trial in Ovarian Cancer Lawsuits .... The world's largest maker of health-care products faces accusations by the family of a woman who died that it knew decades ago that talc, the Earth's softest mineral, was linked to ovarian cancer .... Bloomberg

2/3 Brintellix Tries for New Indication: Confused Thinking Tied to Depression
This antidepressant may be no better than cheaper alternatives. But demand could soon soar .... The drug makers behind Brintellix are betting they can give it a boost by marketing it to treat a whole new category of depression symptoms -- namely, cloudy thinking. .... Stat News

2/3 Ketamine Now Mainstream; Boasts 75% Success Rate
Onetime party drug hailed as miracle for treating severe depression .... A growing number of academic medical centers, including Yale University, the University of California at San Diego, the Mayo Clinic and the Cleveland Clinic, have begun offering ketamine treatments off-label for severe depression, as has Kaiser Permanente in Northern California .... Washington Post

2/3 His Life Mission: End Drug Patents
Big Pharma's worst nightmare .... Jamie Love has spent years battling global drug companies, unshakable in his belief that even the world's poorest people should have access to life-saving medicines .... The Guardian

2/3 "Three is the magic number for payers to get more aggressive": PBMs Holding Fire on PCSK9 Inhibitors
With PCSK9s, payers say, 'Let the market decide' .... Several months after introduction many payers haven't yet anointed one PCSK9 over the next. Nor have they publicly taken the makers to task over pricing, positioning or anything else .... MMM-Online

2/3 Pfizer Stops Trial; Wall Street Sells Off Related Drug
Pfizer Halts Drug Trial, Investors Flee Axovant .... Pfizer discontinued the PF-05212377 (also known as SAM-760) trial in October of 2015 but only updated the NIH's listing on February 2, making the futility discontinuation public knowledge .... Forbes/Jake King

2/3 Insulin Prices Up 20% in One Year
Patients shocked as insulin prices climb higher .... Express Scripts, the largest U.S. pharmacy-benefit manager, said the price of two prominent brand-name injectable insulins, Lantus and Humalog, rose 22.7 percent and 19.9 percent, respectively, from 2014 to 2015. .... Medical Xpress

2/3 Internet Drug News Fast Takes:
Sanofi launches hunt for Zika vaccine as disease fears grow
Abbott plunges deeper into diagnostics with $5.8bn Alere buy
Pharma Times
Andreessen Horowitz Wants To Bring Biology To The Cloud
Forbes/Steve Dickman
Empliciti on track for European approval in multiple myeloma
Researchers Say JNC8 Recs May Put Some Patients at Risk
HealthDay News

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 2/11/16

If you feel that your intellectual property being infringed
e-mail the webmaster and we will remove the content. 

The information on this site is not meant as medical advice.  Information provided on the site is meant to complement and not replace any advice or information from a health professional.

I am not a doctor - I am a pharmacist.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

We never answer drug or health related questions so please don't e-mail us with your drug related questions. 

If you have a question about a drug that you are taking or if you think you are experiencing a side effect from a drug that you are taking you must get in touch with the doctor who prescribed the drug or the pharmacist who dispensed it to you, not us.

The information contained on this web site is for your information only.  You should never take a drug without a doctor's prescription.   Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

It's foolish to start taking a medicine or stop taking a medicine on your own based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.


Corey Nahman Licensed Pharmacist (State Of NY; Lic #035512)

We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.

Badea, Badea, Badea,
That's All Folks!